MUC1 Aptamer Targeted SERS Nanoprobes

Recently, surface-enhanced Raman scattering (SERS) nanoprobes (NPs) have shown promise in the field of cancer imaging due to their unparalleled signal specificity and high sensitivity. This study reports the development of a DNA aptamer targeted SERS NP. Recently, aptamers are being investigated as a viable alternative to more traditional antibody targeting due to their low immunogenicity and low cost of production. A strategy is developed to functionalize SERS NPs with DNA aptamers, which target Mucin1 (MUC1) in human breast cancer (BC). Thorough in vitro characterization studies demonstrate excellent serum stability and specific binding of the targeted NPs to MUC1. In order to test their in vivo targeting capability, MUC1-targeted SERS NPs are coinjected with nontargeted or blocked MUC1-targeted SERS NPs in BC xenograft mouse models. A two-tumor mouse model with differential expression of MUC1 (MDA-MB-468 and MDA-MB-453) is used to control for active versus passive targeting in the same animals. The results show that the targeted SERS NPs home to the tumors via active targeting of MUC1, with low levels of passive targeting. This strategy is expected to be an advantageous alternative to antibody-based targeting and useful for targeted imaging of tumor extent, progression, and therapeutic response.